Unique lipid cargoes in APOE4 human brain-derived extracellular vesicles recruit cell adhesion molecules and promote tauopathy in Alzheimer's disease., PMID:40502793
Unique lipid cargoes in APOE4 human brain-derived extracellular vesicles recruit cell adhesion molecules and promote tauopathy in Alzheimer's disease., PMID:40502793
β-Amyloid as a new target to suppress tonic PTH hypersecretion in primary hyperparathyroidism., PMID:40492090
β-Amyloid as a new target to suppress tonic PTH hypersecretion in primary hyperparathyroidism., PMID:40492090
Acute targeting of N-terminal tau protein has long-lasting beneficial effects in Tg2576 APP/Aβ mouse model by reducing cognitive impairment, cerebral Aβ-amyloidosis, synaptic remodeling and microgliosis later in life., PMID:40442822
Acute targeting of N-terminal tau protein has long-lasting beneficial effects in Tg2576 APP/Aβ mouse model by reducing cognitive impairment, cerebral Aβ-amyloidosis, synaptic remodeling and microgliosis later in life., PMID:40442822
Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference., PMID:40437880
Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference., PMID:40437880
A Novel Phosphorylated Tau Conformer Implicated in the Tauopathy Pathogenesis of Human Neurons., PMID:40305319
A Novel Phosphorylated Tau Conformer Implicated in the Tauopathy Pathogenesis of Human Neurons., PMID:40305319
Pathological tau activates inflammatory nuclear factor-kappa B (NF-κB) and pT181-Qβ vaccine attenuates NF-κB in PS19 tauopathy mice., PMID:40161741
Pathological tau activates inflammatory nuclear factor-kappa B (NF-κB) and pT181-Qβ vaccine attenuates NF-κB in PS19 tauopathy mice., PMID:40161741
Overlapping presence of β-amyloid, tau, p-tau, and α-synuclein in skin nerve fibers in Alzheimer's disease., PMID:40042672
Antibody-level Bacteria Grabbing by "Mechanic Invasion" of Bioinspired Hedgehog Artificial Mesoporous Nanostructure for Hierarchical Dynamic Identification and Light-Response Sterilization., PMID:39972680
Antibody-level Bacteria Grabbing by "Mechanic Invasion" of Bioinspired Hedgehog Artificial Mesoporous Nanostructure for Hierarchical Dynamic Identification and Light-Response Sterilization., PMID:39972680
Associations of Cerebrospinal Fluid Orexin-A, Alzheimer Disease Biomarkers, and Cognitive Performance., PMID:39957622
Associations of Cerebrospinal Fluid Orexin-A, Alzheimer Disease Biomarkers, and Cognitive Performance., PMID:39957622
Distinct subcellular localization of tau and alpha-synuclein in lewy body disease., PMID:39838428
Distinct subcellular localization of tau and alpha-synuclein in lewy body disease., PMID:39838428
Analytical Validation and Performance of a Blood-Based P-tau217 Diagnostic Test for Alzheimer Disease., PMID:39836199
Analytical Validation and Performance of a Blood-Based P-tau217 Diagnostic Test for Alzheimer Disease., PMID:39836199
Enhancing biosensing of trace tau protein in clinical samples via emergence macroscopic directed aggregation., PMID:39824699
Enhancing biosensing of trace tau protein in clinical samples via emergence macroscopic directed aggregation., PMID:39824699
Analytical and clinical performance of eight Simoa® and Lumipulse® assays for automated measurement of plasma p-tau181 and p-tau217., PMID:39702308
Analytical and clinical performance of eight Simoa® and Lumipulse® assays for automated measurement of plasma p-tau181 and p-tau217., PMID:39702308
Antibody-mediated degradation of 4R-tau restores mitochondrial membrane polarization in human induced pluripotent stem cell-derived neurons with the MAPT 10+16 mutation., PMID:39665388
Antibody-mediated degradation of 4R-tau restores mitochondrial membrane polarization in human induced pluripotent stem cell-derived neurons with the MAPT 10+16 mutation., PMID:39665388
Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer's disease, positive for plasma p-tau217., PMID:39580468
Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer's disease, positive for plasma p-tau217., PMID:39580468
Degradation fragments of Tau and type IV collagen as serum biomarkers in patients with recurrent glioblastoma treated with nivolumab and bevacizumab., PMID:39499486
Degradation fragments of Tau and type IV collagen as serum biomarkers in patients with recurrent glioblastoma treated with nivolumab and bevacizumab., PMID:39499486
Amyloid-β predominant Alzheimer's disease neuropathologic change., PMID:39417691
Amyloid-β predominant Alzheimer's disease neuropathologic change., PMID:39417691
Development and characterization of novel anti-acetylated tau monoclonal antibodies to probe pathogenic tau species in Alzheimer's disease., PMID:39396065
Development and characterization of novel anti-acetylated tau monoclonal antibodies to probe pathogenic tau species in Alzheimer's disease., PMID:39396065
The cellular prion protein does not affect tau seeding and spreading of sarkosyl-insoluble fractions from Alzheimer's disease., PMID:39284839
The cellular prion protein does not affect tau seeding and spreading of sarkosyl-insoluble fractions from Alzheimer's disease., PMID:39284839
Phosphorylation of tau at a single residue inhibits binding to the E3 ubiquitin ligase, CHIP., PMID:39266525
Phosphorylation of tau at a single residue inhibits binding to the E3 ubiquitin ligase, CHIP., PMID:39266525
In-situ nanozyme catalytic amplification coupled with a universal antibody orientation strategy based electrochemical immunosensor for AD-related biomarker., PMID:39241336
In-situ nanozyme catalytic amplification coupled with a universal antibody orientation strategy based electrochemical immunosensor for AD-related biomarker., PMID:39241336
MAPT mutations associated with familial tauopathies lead to formation of conformationally distinct oligomers that have cross-seeding ability., PMID:39145409
MAPT mutations associated with familial tauopathies lead to formation of conformationally distinct oligomers that have cross-seeding ability., PMID:39145409
Proteostasis as a fundamental principle of Tau immunotherapy., PMID:39074206
Proteostasis as a fundamental principle of Tau immunotherapy., PMID:39074206
IgLON5-IgG: Innocent Bystander or Perpetrator?, PMID:39063198
IgLON5-IgG: Innocent Bystander or Perpetrator?, PMID:39063198
Associations between Microglia and Astrocytic Proteins and Tau Biomarkers across the Continuum of Alzheimer's Disease., PMID:39062786
Associations between Microglia and Astrocytic Proteins and Tau Biomarkers across the Continuum of Alzheimer's Disease., PMID:39062786
An exploratory study of the damage markers NfL, GFAP, and t-Tau, in cerebrospinal fluid and other findings from a patient cohort enriched for suspected autoimmune psychiatric disease., PMID:39048548
An exploratory study of the damage markers NfL, GFAP, and t-Tau, in cerebrospinal fluid and other findings from a patient cohort enriched for suspected autoimmune psychiatric disease., PMID:39048548
iPSC-induced neurons with the V337M MAPT mutation are selectively vulnerable to caspase-mediated cleavage of tau and apoptotic cell death., PMID:39032719
iPSC-induced neurons with the V337M MAPT mutation are selectively vulnerable to caspase-mediated cleavage of tau and apoptotic cell death., PMID:39032719
CCDC50 mediates the clearance of protein aggregates to prevent cellular proteotoxicity., PMID:38869076
CCDC50 mediates the clearance of protein aggregates to prevent cellular proteotoxicity., PMID:38869076
[Human tau N-terminal domain-specific monoclonal antibodies: screening and application in blood detection]., PMID:38783817
[Human tau N-terminal domain-specific monoclonal antibodies: screening and application in blood detection]., PMID:38783817
Identification of high-performing antibodies for the reliable detection of Tau proteoforms by Western blotting and immunohistochemistry., PMID:38761203
Identification of high-performing antibodies for the reliable detection of Tau proteoforms by Western blotting and immunohistochemistry., PMID:38761203
Multiple system atrophy with amyloid-β-predominant Alzheimer's disease neuropathologic change., PMID:38712319
Multiple system atrophy with amyloid-β-predominant Alzheimer's disease neuropathologic change., PMID:38712319
MAPT H2 haplotype and risk of Pick's disease in the Pick's disease International Consortium: a genetic association study., PMID:38631765
Clinical and Pathological Features of FTDP-17 with MAPT p.K298_H299insQ Mutation., PMID:38605589
Clinical and Pathological Features of FTDP-17 with MAPT p.K298_H299insQ Mutation., PMID:38605589
P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathy., PMID:38513667
P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathy., PMID:38513667
A selection and optimization strategy for single-domain antibodies targeting the PHF6 linear peptide within the tau intrinsically disordered protein., PMID:38484799
A selection and optimization strategy for single-domain antibodies targeting the PHF6 linear peptide within the tau intrinsically disordered protein., PMID:38484799
Alzheimer's Disease: Models and Molecular Mechanisms Informing Disease and Treatments., PMID:38247923
Alzheimer's Disease: Models and Molecular Mechanisms Informing Disease and Treatments., PMID:38247923
Clinical Evaluation of Cerebrospinal Fluid p217tau and Neurofilament Light Chain Levels in Patients with Alzheimer's Disease or Other Neurological Diseases., PMID:38007650
Clinical Evaluation of Cerebrospinal Fluid p217tau and Neurofilament Light Chain Levels in Patients with Alzheimer's Disease or Other Neurological Diseases., PMID:38007650
Specific serum autoantibodies predict the development and progression of Alzheimer's disease with high accuracy., PMID:37989443
Specific serum autoantibodies predict the development and progression of Alzheimer's disease with high accuracy., PMID:37989443
Altered plasma protein profiles in genetic FTD - a GENFI study., PMID:37968725
Altered plasma protein profiles in genetic FTD - a GENFI study., PMID:37968725
Diligent Design Enables Antibody-ASO Conjugates with Optimal Pharmacokinetic Properties., PMID:37916986
Diligent Design Enables Antibody-ASO Conjugates with Optimal Pharmacokinetic Properties., PMID:37916986
APOE Christchurch-mimetic therapeutic antibody reduces APOE-mediated toxicity and tau phosphorylation., PMID:37791598
APOE Christchurch-mimetic therapeutic antibody reduces APOE-mediated toxicity and tau phosphorylation., PMID:37791598
Primary Feline Tauopathy: Clinical, Morphological, Immunohistochemical, and Genetic Studies., PMID:37760385
Primary Feline Tauopathy: Clinical, Morphological, Immunohistochemical, and Genetic Studies., PMID:37760385
Glial reactivity and T cell infiltration in frontotemporal lobar degeneration with tau pathology., PMID:37703311
Glial reactivity and T cell infiltration in frontotemporal lobar degeneration with tau pathology., PMID:37703311
Phosphorylation of a Cleaved Tau Proteoform at a Single Residue Inhibits Binding to the E3 Ubiquitin Ligase, CHIP., PMID:37645969
Phosphorylation of a Cleaved Tau Proteoform at a Single Residue Inhibits Binding to the E3 Ubiquitin Ligase, CHIP., PMID:37645969
Cell-specific MAPT gene expression is preserved in neuronal and glial tau cytopathologies in progressive supranuclear palsy., PMID:37354322
Cell-specific MAPT gene expression is preserved in neuronal and glial tau cytopathologies in progressive supranuclear palsy., PMID:37354322
Mutation ∆K281 in MAPT causes Pick's disease., PMID:37351604
Mutation ∆K281 in MAPT causes Pick's disease., PMID:37351604
Aβ1-6A2V(D) peptide, effective on Aβ aggregation, inhibits tau misfolding and protects the brain after traumatic brain injury., PMID:37198260
Aβ1-6A2V(D) peptide, effective on Aβ aggregation, inhibits tau misfolding and protects the brain after traumatic brain injury., PMID:37198260
Anterograde and Retrograde Propagation of Inoculated Human Tau Fibrils and Tau Oligomers in a Non-Transgenic Rat Tauopathy Model., PMID:37189622
Anterograde and Retrograde Propagation of Inoculated Human Tau Fibrils and Tau Oligomers in a Non-Transgenic Rat Tauopathy Model., PMID:37189622
Assessment of tau phosphorylation and β-amyloid pathology in human drug-resistant epilepsy., PMID:37052232
Assessment of tau phosphorylation and β-amyloid pathology in human drug-resistant epilepsy., PMID:37052232
Thioflavin S Staining and Amyloid Formation Are Unique to Mixed Tauopathies., PMID:36861683
Thioflavin S Staining and Amyloid Formation Are Unique to Mixed Tauopathies., PMID:36861683
For research use only. Not for human or drug use.
